SG11202003978UA - Molecules that bind to cd137 and psma - Google Patents

Molecules that bind to cd137 and psma

Info

Publication number
SG11202003978UA
SG11202003978UA SG11202003978UA SG11202003978UA SG11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA
Authority
SG
Singapore
Prior art keywords
psma
bind
molecules
Prior art date
Application number
SG11202003978UA
Other languages
English (en)
Inventor
Verena Brucklacher-Waldert
Carolyn Edwards
James Legg
Jayesh Majithiya
Christine Rossant
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718735.2A external-priority patent/GB201718735D0/en
Priority claimed from GBGB1718734.5A external-priority patent/GB201718734D0/en
Priority claimed from GBGB1808589.4A external-priority patent/GB201808589D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of SG11202003978UA publication Critical patent/SG11202003978UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202003978UA 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma SG11202003978UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1718735.2A GB201718735D0 (en) 2017-11-13 2017-11-13 Bispecific molecules that bind to CD137 and PSMA
GBGB1718734.5A GB201718734D0 (en) 2017-11-13 2017-11-13 Single domain antibodies that bind to CD137
GBGB1808589.4A GB201808589D0 (en) 2018-05-24 2018-05-24 Single domain antibodies that bind CD137
PCT/GB2018/053280 WO2019092452A1 (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma

Publications (1)

Publication Number Publication Date
SG11202003978UA true SG11202003978UA (en) 2020-05-28

Family

ID=64457031

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202003912RA SG11202003912RA (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137
SG11202003978UA SG11202003978UA (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202003912RA SG11202003912RA (en) 2017-11-13 2018-11-13 Single Domain Antibodies that Bind to CD137

Country Status (10)

Country Link
US (2) US20200362051A1 (zh)
EP (2) EP3710477A1 (zh)
JP (3) JP7312168B2 (zh)
KR (2) KR20200083574A (zh)
CN (2) CN111683968A (zh)
AU (2) AU2018363292A1 (zh)
CA (2) CA3082321A1 (zh)
IL (2) IL274370A (zh)
SG (2) SG11202003912RA (zh)
WO (2) WO2019092451A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478293A (zh) 2016-01-12 2023-07-25 克雷森多生物制剂有限公司 治疗分子
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CA3082321A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
JP2020132572A (ja) * 2019-02-20 2020-08-31 旭化成株式会社 シラノール組成物、硬化物及び製造方法
CA3136598A1 (en) * 2019-05-15 2021-11-19 Grainne Dunlevy Binding molecules
AU2020329466A1 (en) * 2019-08-12 2021-05-27 Abl Bio Inc. Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
CN114269788A (zh) * 2019-11-13 2022-04-01 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子及其应用
JP2023502652A (ja) * 2019-11-18 2023-01-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ７９キメラ抗原受容体、ｃａｒ－ｔ細胞、及びそれらの使用
CA3183462A1 (en) * 2020-06-30 2022-01-06 Lei Shi 4-1bb-binding protein and use thereof
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
EP4341293A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-cd137 antibodies and methods of use
CN117460745A (zh) * 2021-05-21 2024-01-26 百济神州有限公司 抗gpc3和抗cd137多特异性抗体及使用方法
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用
KR20240049829A (ko) * 2021-08-31 2024-04-17 라노바 메디신즈 리미티드 컴파니 항-4-1bb 나노바디
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
BRPI0511782B8 (pt) * 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
TWI726842B (zh) * 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
ES2701061T5 (es) * 2014-10-22 2022-05-09 Crescendo Biologics Ltd Ratones transgénicos
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CN108112253B (zh) * 2015-05-18 2022-09-23 皮里斯制药有限公司 抗癌融合多肽
RU2018116402A (ru) * 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
IL260530B2 (en) * 2016-01-11 2024-01-01 Inhibrx Inc Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses
CN116478293A (zh) * 2016-01-12 2023-07-25 克雷森多生物制剂有限公司 治疗分子
KR102426765B1 (ko) * 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
AU2017271601A1 (en) * 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CA3075969A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG Multispecific antibody
CA3082321A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137

Also Published As

Publication number Publication date
EP3710477A1 (en) 2020-09-23
CN111699197A (zh) 2020-09-22
WO2019092452A1 (en) 2019-05-16
CN111683968A (zh) 2020-09-18
JP2023126951A (ja) 2023-09-12
SG11202003912RA (en) 2020-05-28
US20200362047A1 (en) 2020-11-19
WO2019092451A1 (en) 2019-05-16
EP3710478A1 (en) 2020-09-23
AU2018363291A1 (en) 2020-05-21
JP2021502104A (ja) 2021-01-28
AU2018363292A1 (en) 2020-05-21
CA3082297A1 (en) 2019-05-16
KR20200080304A (ko) 2020-07-06
IL274370A (en) 2020-06-30
JP2021502810A (ja) 2021-02-04
IL274371A (en) 2020-06-30
KR20200083574A (ko) 2020-07-08
US20200362051A1 (en) 2020-11-19
CA3082321A1 (en) 2019-05-16
JP7312168B2 (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
IL274371A (en) Compounds that bind CD137 and PSMA
IL273631A (en) Special hpv molecules bind
IL266100B (en) Multimeric il-15 based molecules
HK1252863A1 (zh) 結合cd22的抗體分子
HK1254337A1 (zh) April的抗體分子及其用途
IL254223A (en) CD20 binding compounds and their uses
GB201612520D0 (en) Binding molecules
SG11201705583XA (en) Cxcr4 binding molecules
GB201702091D0 (en) Specific binding molecules
SG11202004904XA (en) Binding molecules that specifically bind to tau
HK1258317A1 (zh) 對asct2具有特異性的結合分子及其用途
IL269752B (en) fgfr3 binding molecules
IL259883A (en) Antibody molecules that bind tnf alpha
GB201718735D0 (en) Bispecific molecules that bind to CD137 and PSMA
GB201718734D0 (en) Single domain antibodies that bind to CD137
GB201508729D0 (en) Binding molecules